000756 新华制药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,734,1663.64%8,100,8457,502,9876,560,0786,005,587
减:营业总成本6,337,0894.93%7,530,9057,020,4786,173,7365,585,070
    其中:营业成本5,151,91311.82%5,709,1425,465,6564,786,4104,190,990
               财务费用10,2149.12%16,35132,01952,90383,710
               资产减值损失(48,314)8.96%(69,283)(43,526)(33,267)(45,159)
公允价值变动收益------------
投资收益8,400-13.31%9,5838,3658,0175,611
    其中:对联营企业和合营企业的投资收益217-85.73%1,418447(1,089)(2,978)
营业利润398,270-10.88%534,582476,707425,591422,485
利润总额392,918-12.00%532,686471,774421,233411,638
减:所得税费用37,468-18.88%26,57945,66559,15964,525
净利润355,449-11.20%506,107426,110362,074347,113
减:非控股权益11,36936.63%9,59515,04713,52622,254
股东净利润344,080-12.22%496,512411,063348,548324,860

市场价值指针
每股收益 (元) *0.500-13.79%0.7400.6200.5600.520
每股派息 (元) *0.025--0.2500.2000.1500.150
每股净资产 (元) *7.1397.52%6.7496.1625.5285.184
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容